• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

Sofinnova

Laboratory testing facilities
Sofinnova holds EUR 150m close for third biotech fund

Impact fund has made two investments as of its interim close and expects to make 10-12 in total

  • Venture
  • 17 November 2021
Surgery software and tools
Consortium backs €38.75m series-B for Tissium

France-based wound dressing developer previously raised €30.5m at the series-A stage

  • Expansion
  • 20 November 2019
Fund management diversification
French GPs opt for organic diversification

Recent fund closes show that organic diversification is still a valid option for some GPs and VCs willing to step out of their comfort zones

  • GPs
  • 25 June 2019
Pressure gauge
Sofinnova et al. invest €20m in Afyren

France-based biotech business Afyren plans to commercialise its products in 2020

  • Expansion
  • 13 February 2019
Diabetes medication and testing equipment
Sofinnova et al. back €27m series-C for Limflow

BPI France and Balestier, a Singaporean family fund, also take part in the financing

  • Expansion
  • 18 April 2018
Used bank notes
Sofinnova closes biotech fund on $650m hard-cap

Fund's different generations have received a combined $2bn of committments in total

  • Funds
  • 20 October 2016
Endoscopes and other medical devices
Sofinnova leads €22.5m Gecko Biomedical round

Extension to series-A round also includes BPI France, Omnes, CM-­CIC Innovation and CapDecisif

  • Early-stage
  • 17 March 2016
Biotechnology and DNA sequencing
Sofinnova and Imperial's Mission Therapeutics raises £60m

Investment led by Woodford Patient Capital Trust and saw existing backers re-up

  • Early-stage
  • 02 February 2016
Sofinnova et al. in €72.8m series-C round for Merus

Third largest round observed by unquote" in Benelux so far in 2015

  • Benelux
  • 28 August 2015
VC backers divest GlycoVaxyn to GSK

Deal values biopharmaceutical company at $212m

  • DACH
  • 11 February 2015
VC-backed Ascendis raises $108m in IPO

Listing priced at $18 per share

  • Nordics
  • 29 January 2015
Ascendis completes $60m series-D

A total of seven investors comitted capital to the round

  • Expansion
  • 02 December 2014
Auris’ delayed IPO lists below initial price range

Number of shares on offer increased by more than 35% but price almost halved

  • DACH
  • 08 August 2014
Sofinnova-backed Auris announces price range

Float expected to be worth between £69-82m

  • DACH
  • 23 July 2014
VC-backed OpenERP raises $10m

Company to rebrand as Odoo as part of the deal

  • Benelux
  • 19 May 2014
Sofinnova leads CHF 32m round for ObsEva

Sofinnova Partners has led a CHF 32m series-A round for Swiss biopharma company ObsEva.

  • DACH
  • 29 August 2013
John Holloway from EIF
European venture: patience rewarded

Patience rewarded

  • Venture
  • 02 August 2013
Idinvest leads €34m round for Crocus

Idinvest Partners has led a €34m funding round for Crocus Technology, a French supplier of magnetic semiconductors and sensors, with participation from a consortium of new and existing backers.

  • Expansion
  • 10 July 2013
Emerald Technology Ventures et al. back MetGen

Emerald Technology Ventures and several other backers have invested in a series-A financing round for MetGen Oy, a Finnish industrial biotech company.

  • Nordics
  • 05 June 2013
CDC Entreprises and Sofinnova invest €8m in MedDay

CDC Entreprises and Sofinnova Partners have made an €8m equity investment in French biotech firm MedDay.

  • France
  • 09 April 2013
Aledia raises €10m in first funding round

Sofinnova Partners, Braemar Energy Ventures, Demeter Partners and CEA Investissement have participated in a €10m funding round for French LED developer Aledia.

  • France
  • 03 April 2013
CDC leads €10m round for McPhy Energy

CDC Entreprises has invested €5m as part of a €10m round for French hydrogen storage specialist McPhy Energy.

  • France
  • 17 January 2013
venture1new
Venture's Olympic performance

Venture's Olympic performance

  • UK / Ireland
  • 10 August 2012
Early-stage values
Declining activity belies venture successes

Although European venture capital activity decreased by 12% to €974m last year, 2011 saw a number of sizeable fund closes as well strong exits, indicating fresh appetite for the asset class.

  • Venture
  • 10 April 2012
1 2
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013